bullish
Samsung BioLogics' Revised Valuation Based on P/B Multiple
298 Views27 Oct 2016 05:11
In another regulatory filing, Samsung BioLogics presented a revised valuation based on P/B multiple. Obviously, there are still many people who are...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction09 Nov 2016
- Samsung BioLogics IPO - Why Investors Are Excited & Concerned01 Nov 2016
- Samsung BioLogics IPO Price Is Set At Highest End (₩136,000) - 3 Points to Consider27 Oct 2016
- Samsung BioLogics' Revised Valuation Based on P/B Multiple27 Oct 2016
- 3 Main Debatable Points to Be Discussed in Samsung BioLogics NDR This Week20 Oct 2016
- Samsung BioLogics IPO Part 3 - Valuation05 Oct 2016
x